BAZ2A (TIP5) is involved in epigenetic alterations in Prostate cancer and its overexpression predicts disease recurrence

Nature Genetics

Volumn 47, Issue 1, 2015, Pages

  Gu, Lei ^a,i,j   Frommel, Sandra C ^b   Oakes, Christopher C ^a   Simon, Ronald ^c   Grupp, Katharina ^c   Gerig, Cristina Y ^b   Bär, Dominik ^b   Robinson, Mark D ^b   Baer, Constance ^a   Weiss, Melanie ^a   Gu, Zuguang ^a   Schapira, Matthieu ^d   Kuner, Ruprecht ^a   Sültmann, Holger ^a   Provenzano, Maurizio ^e   Yaspo, Marie Laure ^f   Brors, Benedikt ^a   Korbel, Jan ^g   Schlomm, Thorsten ^c   Sauter, Guido ^c   Eils, Roland ^a,h   Plass, Christoph ^a   Santoro, Raffaella ^b   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^g EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j BOSTON CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BAZ2A PROTEIN; MEMBRANE PROTEIN; RIBOSOME RNA; TUMOR MARKER; UNCLASSIFIED DRUG; BAZ2A PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; NONHISTONE PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; RNA; TUMOR PROTEIN;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; EPIGENETICS; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC REGULATION; HUMAN; HUMAN TISSUE; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT DISEASE; ADENOCARCINOMA; BIOSYNTHESIS; CELL DIVISION; CPG ISLAND; DNA METHYLATION; EPIGENETIC REPRESSION; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROSTATE TUMOR; PROTEIN ANALYSIS; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CELL DIVISION; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; CPG ISLANDS; DNA METHYLATION; EPIGENETIC REPRESSION; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN INTERACTION MAPPING; RNA, NEOPLASM; RNA, RIBOSOMAL; UP-REGULATION;

EID: 84924705911     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3165     Document Type: Article

References (69)

1. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
2. Weischenfeldt, J. et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23, 159-170 (2013).
3. Plass, C. et al. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet. 14, 765-780 (2013).
4. Kim, J. H. et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res. 21, 1028-1041 (2011).
5. Kron, K. et al. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. Clin. Cancer Res. 19, 3450-3461 (2013).
6. Aryee, M. J. et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl. Med. 5, 169ra10 (2013).
7. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
8. Bracken, A. P. et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323-5335 (2003).
9. Hinz, S. et al. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder. J. Cancer Res. Clin. Oncol. 134, 331-336 (2008).
10. Bachmann, I. M. et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24, 268-273 (2006).
11. Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 100, 11606-11611 (2003).
12. Crea, F., Paolicchi, E., Marquez, V. E. & Danesi, R. Polycomb genes and cancer: time for clinical application? Crit. Rev. Oncol. Hematol. 83, 184-193 (2012).
13. Tsang, D. P. & Cheng, A. S. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J. Gastroenterol. Hepatol. 26, 19-27 (2011).
14. Richly, H., Aloia, L. & Di Croce, L. Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis. 2, e204 (2011).
15. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
16. Brase, J. C. et al. TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer 11, 507 (2011).
17. Santoro, R., Li, J. & Grummt, I. The nucleolar remodeling complex NoRC mediates heterochromatin formation and silencing of ribosomal gene transcription. Nat. Genet. 32, 393-396 (2002).
18. Zhou, Y., Santoro, R. & Grummt, I. The chromatin remodeling complex NoRC targets HDAC1 to the ribosomal gene promoter and represses RNA polymerase I transcription. EMBO J. 21, 4632-4640 (2002).
19. Guetg, C., Scheifele, F., Rosenthal, F., Hottiger, M. O. & Santoro, R. Inheritance of silent rDNA chromatin is mediated by PARP1 via noncoding RNA. Mol. Cell 45, 790-800 (2012).
20. Hein, N., Hannan, K. M., George, A. J., Sanij, E. & Hannan, R. D. The nucleolus: an emerging target for cancer therapy. Trends Mol. Med. 19, 643-654 (2013).
21. Bywater, M. J. et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 22, 51-65 (2012).
22. Cho, S. et al. MiRGator v3.0: a microRNA portal for deep sequencing, expression profiling and mRNA targeting. Nucleic Acids Res. 41, D252-D257 (2013).
23. Dong, Y. J. et al. MiR-133a inhibits colorectal cancer cell growth by direct targeting E3 ubiquitin ligase RFFL and activating p53-p21CIP1/WAF1 pathway. Gastroenterology 142, S185 (2012).
24. Uchida, Y. et al. MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol. Oncol. 31, 115-123 (2013).
25. Ji, F. et al. MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. Bone 56, 220-226 (2013).
26. Tao, J. et al. MicroRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol. Rep. 27, 1967-1975 (2012).
27. Kojima, S. et al. Tumor suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Eur. Urol. Suppl. 106, 405-413 (2012).
28. Li, J., Santoro, R., Koberna, K. & Grummt, I. The chromatin remodeling complex NoRC controls replication timing of rRNA genes. EMBO J. 24, 120-127 (2005).
29. Santoro, R., Lienemann, P. & Fussenegger, M. Epigenetic engineering of ribosomal RNA genes enhances protein production. PLoS ONE 4, e6653 (2009).
30. Guetg, C. et al. The NoRC complex mediates the heterochromatin formation and stability of silent rRNA genes and centromeric repeats. EMBO J. 29, 2135-2146 (2010).
31. Grummt, I. Life on a planet of its own: regulation of RNA polymerase I transcription in the nucleolus. Genes Dev. 17, 1691-1702 (2003).
32. Li, H., Chen, X., Calhoun-Davis, T., Claypool, K. & Tang, D. G. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res. 68, 1820-1825 (2008).
33. Sheng, X. et al. Isolation and enrichment of PC-3 prostate cancer stem-like cells using MACS and serum-free medium. Oncol. Lett. 5, 787-792 (2013).
34. low increase tumor angiogenesis. Mol. Cancer 9, 319 (2010).
35. Doherty, R. E., Haywood-Small, S. L., Sisley, K. & Cross, N. A. Aldehyde dehydrogenase activity selects for the holoclone phenotype in prostate cancer cells. Biochem. Biophys. Res. Commun. 414, 801-807 (2011).
36. Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J. & Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946-10951 (2005).
37. Irshad, S. et al. A molecular signature predictive of indolent prostate cancer. Sci. Transl. Med. 5, 202ra122 (2013).
38. Yu, Y. P. et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22, 2790-2799 (2004).
39. Wang, Y. et al. Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 7, 748-760 (2005).
40. Mori, Y. et al. Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr. Relat. Cancer 18, 465-478 (2011).
41. Kinoshita, M., Nakagawa, T., Shimizu, A. & Katsuoka, Y. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Int. J. Urol. 12, 390-397 (2005).
42. Novak, P. et al. Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res. 66, 10664-10670 (2006).
43. Zhang, J. S., Gong, A. & Young, C. Y. ZNF185, an actin-cytoskeleton-associated growth inhibitory LIM protein in prostate cancer. Oncogene 26, 111-122 (2007).
44. Cheng, X. F. et al. Growth inhibitory effect of Kruppel-like factor 6 on human prostatic carcinoma and renal carcinoma cell lines. Tohoku J. Exp. Med. 216, 35-45 (2008).
45. Wang, N. et al. Screening and identification of distant metastasis-related differentially expressed genes in human squamous cell lung carcinoma. Anat. Rec. (Hoboken) 295, 748-757 (2012).
46. Maksimovic, J., Gordon, L. & Oshlack, A. SWAN: subset-quantile within array normalization for Illumina Infinium HumanMethylation450 BeadChips. Genome Biol. 13, R44 (2012).
47. Lee, W. H. et al. Cytidine methylation of regulatory sequences near the p-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91, 11733-11737 (1994).
48. Yu, J. et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454 (2010).
49. Issa, J. P. CpG island methylator phenotype in cancer. Nat. Rev. Cancer 4, 988-993 (2004).
50. Zouridis, H. et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci. Transl. Med. 4, 156ra140 (2012).
51. McCabe, M. T., Lee, E. K. & Vertino, P. M. A multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation. Cancer Res. 69, 282-291 (2009).
52. Cho, N. Y. et al. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J. Pathol. 211, 269-277 (2007).
53. Shyr, C. R. et al. Tumor suppressor PAX6 functions as androgen receptor co-repressor to inhibit prostate cancer growth. Prostate 70, 190-199 (2010).
54. Nguyen, A. H. et al. Gata3 antagonizes cancer progression in Pten-deficient prostates. Hum. Mol. Genet. 22, 2400-2410 (2013).
55. Kypta, R. M. & Waxman, J. Wnt/β-catenin signalling in prostate cancer. Nat. Rev. Urol. 9, 418-428 (2012).
56. Kashat, M. et al. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am. J. Transl. Res. 4, 432-442 (2012).
57. Östling, P. et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 71, 1956-1967 (2011).
58. Shi, X. B. et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 32, 4130-4138 (2013).
59. Dawson, M. A., Kouzarides, T. & Huntly, B. J. Targeting epigenetic readers in cancer. N. Engl. J. Med. 367, 647-657 (2012).
60. Zhou, Y. & Grummt, I. The PHD finger/bromodomain of NoRC interacts with acetylated histone H4K16 and is sufficient for rDNA silencing. Curr. Biol. 15, 1434-1438 (2005).
61. Li, B. & Dewey, C.N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
62. Metzig, M. et al. An RNAi screen identifies USP2 as a factor required for TNF-α-induced NF-κB signaling. Int. J. Cancer 129, 607-618 (2011).
63. Santoro, R. Analysis of chromatin composition of repetitive sequences: the ChIP-Chop assay. Methods Mol. Biol. 1094, 319-328 (2014).
64. Subramanian, A., Kuehn, H., Gould, J., Tamayo, P. & Mesirov, J.P. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 23, 3251-3253 (2007).
65. Schlomm, T. et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod. Pathol. 21, 1371-1378 (2008).
66. Mirlacher, M. & Simon, R. Recipient block TMA technique. Methods Mol. Biol. 664, 37-44 (2010).
67. Minner, S. et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71, 281-288 (2011).
68. Grupp, K. et al. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Mod. Pathol. 26, 733-742 (2013).
69. Muller, J. et al. Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. Int. J. Cancer 132, 1333-1340 (2013).